Building The OHDSI Evidence Network, Session II

OHDSI Community Call
July 23, 2024 • 11 am ET
## Upcoming Community Calls

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 23</td>
<td>Building The OHDSI Evidence Network Sprint</td>
</tr>
<tr>
<td>July 30</td>
<td>Advances in Patient-Level Prediction</td>
</tr>
<tr>
<td>Aug. 6</td>
<td>Building The OHDSI Evidence Network Sprint</td>
</tr>
<tr>
<td>Aug. 13</td>
<td>Global Symposium Plenary and Tutorial Preview</td>
</tr>
<tr>
<td>Aug. 20</td>
<td>Building The OHDSI Evidence Network Sprint</td>
</tr>
<tr>
<td>Aug. 27</td>
<td>canceled due to ISPE 2024</td>
</tr>
<tr>
<td>Sept. 3</td>
<td>New Standardized Vocabularies Release</td>
</tr>
<tr>
<td>Sept. 10</td>
<td>Asia-Pacific Regional Updates</td>
</tr>
</tbody>
</table>
July 30: Patient-Level Prediction

Jenna Reps
Johnson & Johnson

Chen Yanover
KI Research Institute

Henrik John
Erasmus MC

Alexander Saelmans
Erasmus MC

Egill Friðgeirsson
Erasmus MC

Ross Williams
Erasmus MC
Three Stages of The Journey

Where Have We Been?
Where Are We Now?
Where Are We Going?
Congratulations to the team of Tom Seinen, Jan Kors, Erik van Mulligen, and Peter Rijnbeek on the publication of Annotation-preserving machine translation of English corpora to validate Dutch clinical concept extraction tools in JAMIA.
Three Stages of The Journey

Where Have We Been?
Where Are We Now?
Where Are We Going?
<table>
<thead>
<tr>
<th>Date</th>
<th>Time (ET)</th>
<th>Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday</td>
<td>12 pm</td>
<td>Latin America</td>
</tr>
<tr>
<td>Wednesday</td>
<td>4 pm</td>
<td>Vulcan/OHDSI</td>
</tr>
<tr>
<td>Wednesday</td>
<td>7 pm</td>
<td>Medical Imaging</td>
</tr>
<tr>
<td>Thursday</td>
<td>9:30 am</td>
<td>Network Data Quality</td>
</tr>
<tr>
<td>Thursday</td>
<td>7 pm</td>
<td>Dentistry</td>
</tr>
<tr>
<td>Friday</td>
<td>9 am</td>
<td>Phenotype Development &amp; Evaluation</td>
</tr>
<tr>
<td>Friday</td>
<td>10 am</td>
<td>GIS-Geographic Information System</td>
</tr>
<tr>
<td>Friday</td>
<td>11:30 am</td>
<td>Steering Group</td>
</tr>
<tr>
<td>Monday</td>
<td>9 am</td>
<td>Vaccine Vocabulary</td>
</tr>
<tr>
<td>Monday</td>
<td>10 am</td>
<td>CDM Survey Subgroup</td>
</tr>
<tr>
<td>Monday</td>
<td>10 am</td>
<td>Healthcare Systems Interest Group</td>
</tr>
<tr>
<td>Tuesday</td>
<td>12 pm</td>
<td>CDM Vocabulary Subgroup</td>
</tr>
</tbody>
</table>
# OHDSI2024 Conference Agenda

## Agenda • Wednesday, Oct. 23

<table>
<thead>
<tr>
<th>Time (ET)</th>
<th>Topic (Presenters)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:30 am</td>
<td>Registration and Lite Breakfast</td>
</tr>
<tr>
<td>8:30 - 9:15 am</td>
<td>State of the OHDSI Community (George Hripcsak, Columbia Univ.)</td>
</tr>
<tr>
<td>9:15 - 10:15 am</td>
<td><strong>Plenary: Clinical Insights from LEGEND-T2DM</strong>&lt;br&gt;(Moderator: Aline Pedroso, Brazil)&lt;br&gt;Comparative Effectiveness of Second-line Antihyperglycemic Agents (Arya Aminorrosa, Yale Univ.)&lt;br&gt;Effectiveness of First-line Antihyperglycemia Agents (Phyllis Tangaras, Yale Univ.)&lt;br&gt;Comparative Safety of SGLT2 for Risk of Diabetic Ketoacidosis (Hannah Yang/Evan Minty, Univ. of Calgary)&lt;br&gt;Comparative Safety of GLP1 RA and the Risk of Thyroid Tumors (Daniel Morales, Univ. of Dundee)</td>
</tr>
<tr>
<td>10:15 - 10:35 am</td>
<td>Networking Break</td>
</tr>
<tr>
<td>10:35 - 11:20 am</td>
<td><strong>Plenary: Value Proposition for Participating in OHDSI Network Studies like LEGEND-T2DM</strong>&lt;br&gt;(Moderator: Ciar Blacketer, Johnson &amp; Johnson)&lt;br&gt;Reflections from US Department of Veterans Affairs (Scott Duvall, VA)&lt;br&gt;Reflections from SIDIAF (Spain) (Talita Duarte-Salles, IDIAP)&lt;br&gt;Reflections from Taipei Medical University (Thanh-Phuc Phan, Taipei Medical Univ.)&lt;br&gt;Reflections from a Global Commercial Data Provider (Sarah Seager, IQVIA)</td>
</tr>
<tr>
<td>11:20 am - 12 pm</td>
<td><strong>Plenary Q&amp;A: Lessons Learned on LEGEND-T2DM Journey</strong> (Moderator: Fan Bu, Univ. of Michigan; Panelists: LEGEND-T2DM co-authors)</td>
</tr>
<tr>
<td>12 - 12:45 pm</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

**Panelists:**
- OHDSI2024 Conference Panelists

**Time Slots:**
- 12:45 - 1:30 pm: Plenary Panel: JACC-OHDSI Partnership (Moderators: Nicole Pratt, Univ. of South Australia/Marc Suchard, UCLA; Panelists: Harlan Krumholz, Yale Univ/Seng Chan You, Yonsei Univ/Yuan Lu, Yale Univ.)
- 1:30 pm - 2 pm: Plenary Activity: OHDSI Scavenger Hunt - Form Your Network Study Dream Team
- 2 pm - 3 pm: Collaborator Showcase: Posters and Software Demos
- 3 pm - 4 pm: Collaborator Showcase: Lightning Talks
- 4 pm - 5 pm: Collaborator Showcase: Posters and Software Demos
- 5 pm - 6 pm: Closing Talk & Titan Awards (Patrick Ryan, Johnson & Johnson/Columbia Univ.)
- 6 pm - 7 pm: Network Reception

[ohdsi.org/ohdsi2024](http://ohdsi.org/ohdsi2024)
OHDSI2024 Homepage

2024 OHDSI Global Symposium
Oct. 22-24 · New Brunswick, N.J. · Hyatt Regency Hotel

ohdsi.org/ohdsi2024
#OHDSI2024 Registration Is Open!

Registration is OPEN for the 2024 OHDSI Global Symposium, which will be held Oct. 22-24 at the Hyatt Regency Hotel in New Brunswick, N.J., USA.

Tuesday: Tutorials
Wednesday: Plenary/Showcase
Thursday: Workgroup Activities
The Center for Advanced Healthcare Research Informatics (CAHRI) at Tufts Medicine welcomes:

Melissa Haendel, PhD
Director of Precision Health & Translational Informatics and the Sarah Graham Kenan Distinguished Professor in the Department of Genetics at The University of North Carolina at Chapel Hill and co-founder of the Monarch Initiative and the National Covid Cohort Collaborative

‘Journeys across the translational divide: making healthcare and basic research data interoperable’

July 25, 2024, 11am-12pm EST
Virtually via Zoom

Please contact Marty Alvarez at malvarez2@tuftsmedicalcenter.org for calendar invite or questions.
External Validation of the Revised Cardiac Risk Index (RCRI) Clinical Prediction Model in Observational Health Care Databases

Alexander Saelmans, Evan Minty, Peter Rijnbeek, Jenna Reps, Ross Williams

MONDAY

External validation performance of the RCRI model suggests the need for an updated non-cardiac surgery postoperative risk model
Conversion of the Papageorgiou General Hospital EHR to the OMOP Common Data Model

(Papapostolou Grigoris, Chytas Achilleas, Rekcas Alexandros, Bigaki Maria, Zeimpekis Demetrios, Dermentzoglou Lampos, Tortopidis George, Natsiavas Pantelis)
Automated OMOP-CDM pipeline for the new EBMT Registry

(Shirah Cashriel, Nir Assaraf, Ignacio Garcia, Fernando Cid, Freija Descamps)
Incorporating Temporal Information from EHR Data in Clinical Prediction Modelling

(Estelle Lampel, Aniek Markus, Tom Seinen)

Can you increase the predictive performance of models using binning methods or temporal weights?

**Background:** Electronic Health Record (EHR) data is considered both to have a lot of potential for clinical prediction modelling, yet complex and challenging to model. These complexities have led most researchers to bin covariates across a whole observation period or parts of an observation period, ignoring temporal information present in the data.

**Temporality of EHR data**

- **Sparsity:** A patient's events are sparser for certain problems related to specific covariates, so not all covariates are recorded regularly.
- **Integration:** Patient's do not record clinical visits regularly, resulting data is not sampled at regular intervals. Any increase may lead to the loss of patients in such settings.
- **High-observability:** In each visit, different combinations of features are measured. These features are measured at different levels of granularity, and multiple features can represent the same clinical concept.

**Patient Level Prediction** (hospital readmission)

- The point at which a patient experiences an outcome will occur.
- Observation Period: Care is provided.
- Where predictions are observed: Left at random and inconsistently.
- Time: When time needs your attention:
- Risk of event: is anachronistic or at least a priori estimated.

**Methods**

- **Binning Strategies**
  - One Window
    - The observation period is used as an input.
  - Overlapping Window
    - One or more windows that are opened at the index data.
- **Weighting Strategies**
  - Knowledge-based
    - Temporal structuring, based on covariate knowledge.
  - Predictive Weighting
    - Weight is computed based on the probability of a covariate occurring. These probabilities are used as weights.

**Estelle Lampel**

Supervisor(s):
Aniek Markus and Tom Seinen

THURSDAY
FRIDAY

Defining international approaches for the detection of emergent metastasis and the classification of location of metastasis from hospital EHR

(Stelios Theophanous, Sue Cheeseman, Elin Hallan Naderi, Elisabeth Ross, Anne-Lore Bynens, Prabash Galgane Banduge, Petros Kalendralis, Aiara Lobo Gomes, Piers Mahon)
Opening: Sr AD, Real World Evidence & Analytics
Boehringer Ingelheim

SR AD, Real World Evidence & Analytics

Apply Now

< Back
JOB ID - 13278

Description

The purpose of this job is to:

- Generate real world evidence (RWE) to support in-line and pipeline products.
- Provide statistical advice on the analysis of real world data (RWD) to various internal and external stakeholders.
- Contribute to the RWD acquisition strategy and tool evaluation.
Opening: Lead Director, RWE Distributed Research
CVS Health

Lead Director, RWE Distributed Research

Apply

Hybrid
PA - Blue Bell
IL - Northbrook
CT - Hartford
RI - Woonsocket
AZ - Scottsdale

View All Locations

Full time
Posted 6 Days Ago
R0288183

Bring your heart to CVS Health. Every one of us at CVS Health shares a single, clear purpose: Bringing our heart to every moment of your health. This purpose guides our commitment to deliver enhanced human-centric health care for a rapidly changing world. Anchored in our brand — with heart at its center — our purpose sends a personal message that how we deliver our services is just as important as what we deliver.

Our Heart At Work Behaviors™ support this purpose. We want everyone who works at CVS Health to feel empowered by the role they play in transforming our culture and accelerating our ability to innovate and deliver solutions to make health care more personal, convenient and affordable.

About us

Our Work Experience is the combination of everything that's unique about us: our culture, our core values, our company meetings, our commitment to sustainability, our recognition programs, but most importantly, it's our people. Our
Openings: Postdoctoral Fellow, Johns Hopkins Univ.

**PHARMACOEPIDEMIOLOGY POST-DOCTORAL TRAINING PROGRAM**

**Co-Directors:** Caleb Alexander, MD, MS and Jodi Segal, MD, MPH

The Pharmacoepidemiology Training Program at the Johns Hopkins Bloomberg School of Public Health (BSPH) is currently seeking to support postdoctoral fellows. All supported trainees work with core faculty on existing or newly developed research projects on pharmacoepidemiology, so as to optimize the safe and effective use of medicines to treat heart, lung and blood diseases in the United States.

**Deadline for applications:** rolling
Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?
Three Stages of The Journey

Where Have We Been?
Where Are We Now?
Where Are We Going?
July 23: Building The Evidence Network, Session II

Clair Blacketer
Director, Epidemiology Analytics, Janssen Research & Development, Inc.

Paul Nagy
Deputy Director, Johns Hopkins Medicine Technology Innovation Center
Director of Education, Biomedical Informatics and Data Science Graduate Training Programs

- Technical description on what it takes to join the Evidence Network
- Live demo
- Language to support the IRB process
- More!
The weekly OHDSI community call is held every Tuesday at 11 am ET. Everybody is invited! Links are sent out weekly and available at: ohdssi.org/community-calls